Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
4(33%)

Phase Distribution

Ph phase_1
3
25%
Ph phase_2
8
67%
Ph phase_3
1
8%

Phase Distribution

3

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
3(25.0%)
Phase 2Efficacy & side effects
8(66.7%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Terminated4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (25.0%)
Phase 28 (66.7%)
Phase 31 (8.3%)

Trials by Status

terminated433%
completed650%
unknown217%

Recent Activity

0 active trials
Showing 5 of 12
unknownphase_3

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

NCT04722952
terminatedphase_2

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
completedphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

NCT00006009
terminatedphase_2

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

NCT00307827
completedphase_1

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04722952Phase 3

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Unknown
NCT00720629Phase 2

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Terminated
NCT00006009Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

Completed
NCT00307827Phase 2

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Terminated
NCT00032292Phase 1

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Completed
NCT00279435Phase 2

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Terminated
NCT00279422Phase 2

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Terminated
NCT00267306Phase 1

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Completed
NCT00267709Phase 2

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Completed
NCT00267722Phase 2

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Completed
NCT00032305Phase 2

Research Study in Patients With Severe Ulcerative Colitis

Completed
NCT00032279Phase 2

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12